Conv. Plasma
Nigella Sativa

All probiotics studies
Meta analysis
study COVID-19 treatment researchProbioticsProbiotics (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Time to viral- 29% Improvement Relative Risk Probiotics  Veterini et al.  EARLY TREATMENT Is early treatment with probiotics beneficial for COVID-19? Retrospective 30 patients in Indonesia Faster viral clearance with probiotics (not stat. sig., p=0.22) Veterini et al., Indian J. Forensic Me.., Jun 2021 Favors probiotics Favors control

Probiotics Intake as Adjunct Therapy for Infected Health-Care with SARS COV-2

Veterini et al., Indian Journal of Forensic Medicine & Toxicology, 15:2
Jun 2021  
  Source   PDF   All   Meta
Probiotics for COVID-19
18th treatment shown to reduce risk in March 2021
*, now known with p = 0.0000013 from 26 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Small case control analysis with 15 probiotics patients and 15 contol patients, showing no significant differences. PCR tests were only done weekly. Dosage is unknown. 115/LOE/301.4.2/IX/2020.
The immune effects of probiotics are strain-specific.
This study is excluded in the after exclusion results of meta analysis: the observered difference in duration could be caused by the baseline difference in Ct values.
time to viral-, 29.0% lower, relative time 0.71, p = 0.22, treatment 15, control 15.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Veterini et al., 30 Jun 2021, retrospective, Indonesia, peer-reviewed, 6 authors.
This PaperProbioticsAll
Probiotics Intake as Adjunct Therapy for Infected Health-Care with SARS COV-2
Anna Surgean Veterini, Mardiyan Eighty, Kurniawati, Hamzah, Subijanto Marto Soedarmo, Rosita Cita, Sigit Prakoeswa, Damayanti Tinduh, Anesthesiologist Intensivist, Obstetrician, Prof Dermatologist, Anna Surgean Veterini, Dr Jalan Prof, Indonesia Surabaya
Objectives: We performed this case-control observational study to evaluate the comparison of the length of duration of SARS COV-2 infection and the cycle threshold (Ct) value of reverse-transcriptase polymerase chain reaction (RT-PCR) nasopharynx swab between the probiotics intake (case) group and the nonprobiotics intake (control) group. Materials and Methods: Our study was a case-control study involving 15 cases and 15 controls match for RT-PCR positive results. The participants were healthcare consisted of registrars, consultants, and nurses. Each participant was interviewed by google forms using a structured questionnaire to collect sociodemographic characteristics, diet, therapy from a pulmonologist, and adjunct therapy. Results: The total participants consisted of 15 males and 15 females. 4 participants in the case group had febrile, 1 participant with anosmia, 1 participant with febrile, nausea, and vomit before they consumed probiotics, and 9 participants without clinical complaints. One participant in the control group had fevered and cough, 14 participants without clinical complaints-1 participant with co-morbidities in the control group. The data of age, duration of infection, and cycle threshold (Ct) value were in the normal distribution. Analysis results using SPSS 21.00 show no significant differences in the course of disease between the case group and the control group. We found 2 participants in the control group had re-infection, while there was no re-infection in the case group. Conclusion: The present study's finding may imply future care for the viral infection through the immunomodulation mechanism by probiotics consumption.
Conflict of Interests: All authors have no conflict of interest.
Baud, Agri, Gibson, Reid, Giannoni, Using Probiotics to Flatten the Curve of Coronavirus Disease COVID-2019 Pandemic, Front Public Heal
Didari, Solki, Mozaffari, Nikfar, Abdollahi, A systematic review of the safety of probiotics, Expert Opin Drug Saf
Holshue, Debolt, Lindquist, Lofy, Wiesman et al., First case of 2019 novel coronavirus in the United States, N Engl J Med
Infusino, Marazzato, Mancone, Fedele, Mastroianni et al., Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review, Nutrients
Jin, Lian, Hu, Gao, Zheng et al., Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease
Kaijin, Hongliu, Yihong, Qin, Yu et al., Management of corona virus disease-19 (COVID-19): the Zhejiang experience, J Zhejiang Univ
Lin, Jiang, Zhang, Huang, Zhang et al., Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection, Gut
Ng, Tilg, COVID-19 and the gastrointestinal tract: more than meets the eye, Gut
Pan, Zhang, Yang, Poon, Wang, Viral load of SARS-CoV-2 in clinical samples, Lancet Infect Dis, doi:10.1016/S1473-3099(20)30113-4
Wu, Xiao, Zhang, Gu, Lee et al., SARS-CoV-2 titers in wastewater are higher than expected from clinically confirmed cases, medRxiv
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop